logo-loader
Summit Therapeutics PLC

Summit Therapeutics to begin Phase 3 studies of ridinilazol this quarter

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) CEO Glyn Edwards caught up with Proactive Investors at the BIO CEO & Investor Conference in New York.

Edwards says the company expects to begin treating its first patient this quarter in its Phase 3 study of ridinilazol.

Summit is currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and is using its proprietary Discuva Platform to expand its pipeline.

Quick facts: Summit Therapeutics PLC

Price: £0.20

Market: AIM
Market Cap: £32.1 m
Follow

Watch

Summit Therapeutics 'taking leadership role' in development of new antibiotics

Summit Therapeutics PLC's (LON:SUMM) Dr Richard Pye speaks to Proactive London's Andrew Scott following a first quarter update on operational progress across the portfolio. Summit's currently developing three flagship treatments; Ridinilazole, designed to treat Clostridium difficile which...

on 13/6/19

2 min read

;